{"url_path":"/sec/immx/8-k/2026-05-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1873835/0001493152-26-024707-index.html","accession_number":"0001493152-26-024707","cik":"0001873835","ticker":"IMMX","issuer_name":"Immix Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1873835/0001493152-26-024707-index.html","primary_entity_key":"0001873835","primary_entity_name":"Immix Biopharma, Inc."},"word_count":97,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n** **\n\nThe\nfollowing exhibits are furnished with this Current Report on Form 8-K:\n\n \n\n(d)\nExhibits.\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n99.1\n \n[Press\nRelease, dated May 21, 2026.](ex99-1.htm)\n\n104\n \nCover\nPage Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**Immix\nBiopharma, Inc.**\n\n \n \n\nDated:\nMay 21, 2026\n*/s/\nIlya Rachman*\n\n \nIlya\nRachman, M.D., Ph.D.,\n\n \nChief\nExecutive Officer"}